Navigation Links
Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
Date:2/3/2009

9-week repeated dose study in normal mice, was designed to assess toxicity following long-term administration of twice-weekly therapeutic doses (1.5 mg/kg) of SNS-01. This study also included a group of mice that were dosed with a mouse-specific eIF5A siRNA to determine whether there were any toxic effects of suppressing eIF5A in mouse tissues. The change in mean body weight of the treated and untreated mice was exactly the same over the course of the study. In addition to the indices studied in the maximum tolerated dose experiment, hematology was monitored in this experiment. Over the course of six weeks, both the mean red blood cell count (9.8 for control mice, 9.6 for treated mice) and white blood cell count (7.5 for control mice, 7.2 for treated mice) remained consistent, further supporting the conclusion that SNS-01 was non-toxic in these studies. Histopathological analysis of the major organs was conducted by an independent pathologist and revealed no toxicity attributable to SNS-01.

Richard Dondero, Senesco's Vice President of Research and Development commented, "These mouse efficacy studies allowed us to determine a proposed therapeutic dose range for SNS-01. The results of our pre-clinical toxicology and dose-ranging studies indicate a maximum tolerated dose 2-4 times higher than those producing anti-tumor effects in mice."

It is Senesco's goal to file an Investigational New Drug Application for SNS-01 before the end of calendar year 2009. The Company will need to conduct longitudinal toxicology studies and meet with the FDA during this process.

About SNS-01

Senesco's SNS-01 consists of three components: an eIF5A plasmid, an siRNA against eIF5A and polyethyleneiminie (PEI). The eIF5A plasmid upregulates the apoptotic pathways within cancer cells. The siRNA downregulates proinflammatory cytokines, NF-kB and ICAM, which are proliferation factors for multiple myeloma. PEI i
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
2. Senesco Expands on Preclinical Multiple Myeloma Findings
3. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
4. SmartNow.com Announces the Appointment of Dr. Melina Jampolis as Chief Medical Officer
5. Carriage Services Announces Fourth Quarter Earnings Release And Conference Call Schedule
6. Weight Watchers Announces Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Hudsonville Ice Cream Announces Recall
8. American Dietetic Association Announces Agenda for Health Reform
9. Hologic Announces First Quarter Fiscal 2009 Operating Results
10. Arizona Heart Institute Announces FREE Public Forum Featuring Live Viewing of Surgical Procedures Via High-Definition (HD) Satellite
11. Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 15, 2014 For patients with locally advanced pancreatic ... radiation (SABR) may be a promising treatment option, ... not otherwise be an option, according to research ... Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery is ... pancreatic ductal adenocarcinoma (PDA), the most common type ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Brightree® , the leading ... software solutions for the post-acute care industry, today ... of Brightree HME , serving home medical ... well as home infusion pharmacies. The release includes ... purchasing, document management and electronic eligibility checking all ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Synergy Research ... comprehensive report gives the best detail and analysis of ... pulled from a variety of sources, including Ministry of ... Orange Paper will give readers actionable intelligence on clinical ... Paper is relied on by the local and international ...
(Date:9/16/2014)... Valley Cellars and company owner Jay Rosen are featured ... This feature is part of the private cellars section ... company as a whole. , Washington Valley Cellars has ... wine storage solutions for their clients for over 15 ... across the country, especially in New York, New Jersey, ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:Washington Valley Cellars Featured in September Issue of Wine Spectator 2
... , ... Disease Foundation (VDF) is seeking nominations for the 2010 President’s Awards, which recognize those ... disease or have assisted the Foundation in accomplishing its mission in various categories. The ... ...
... ... this health observance day, VIP Smiles, owned by celebrity dentist Dr. Catrise Austin ... Street location by appointment from June 21st - June 28th, 2010. VIP Smiles ... offer the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, which can be administered orally ...
... By combining two relatively inexpensive technologies based on sound and ... women undergo breast biopsies for suspicious lesions. Results of the ... edition and the August print issue of Radiology . ... the potential of diffuse optical tomography in the near infrared ...
... realize international health goals aiming to improve maternal health, ... is crucial. In an editorial published this week entitled ... editors argue that action on maternal health must ... much as it does access to basic medical care. ...
... appendages such as hair, nails, sweat glands and mammary ... the United States, according to a report in the ... of the JAMA/Archives journals. "Cutaneous appendageal carcinomas are ... diverse differentiation that frequently present a diagnostic challenge," the ...
... A new study in the journal Respirology ... acute exacerbations of chronic obstructive pulmonary disease (COPD) experience ... an increased risk of death, compared to those without ... due to impairment of immune responses. Researchers led by ...
Cached Medicine News:Health News:Nominations Wanted for Vascular Disease Foundation President's Awards 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 2Health News:June 27th Is National HIV Testing Day-New York Celebrity Dentist Offers Free Oral Rapid HIV Testing In the Dental Office 3Health News:Noninvasive combination technique may reduce number of breast biopsies 2Health News:Cancers of sweat glands, other skin-related structures may be increasing in United States 2
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... 16, 2014  DNAtrix, Inc., experts in oncolytic ... was treated with the company,s lead product, DNX-2401, ... a randomized, multicenter, open-label Phase Ib study for ... collaboration with leading neurosurgeons and neuro-oncologists in the ... our randomized Phase Ib study of DNX-2401 at ...
(Date:9/16/2014)... Sept. 16, 2014 Henry Schein, Inc. ... provider of health care products and services to ... today that Stanley M. Bergman, Henry Schein,s Chairman of the ... a healthcare services panel at the Leerink Partners ... will be Dr. Stohler, Dean of Columbia University,s ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Henry Schein To Present At The Leerink Partners Services Roundtable 2
... March 28, 2012   Novus Scientific, manufacturer ... the world,s first long-term resorbable (100% absorbable) synthetic mesh, ... data gathered by the Division of Plastic Reconstructive and ... pedicled transverse rectus abdominis myocutaneous (TRAM) flap is a ...
... March 28, 2012  Hawthorn Pharmaceuticals Inc. and its parent ... and certain states a total of $2.8 million to ... LLP that alleged Hawthorn falsely marketed unapproved prescription drugs ... government health care programs. An even bigger ...
Cached Medicine Technology:12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012 212 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012 3Whistleblower Comments on Hawthorn Pharmaceuticals' $2.8 Million Settlement of His Medicaid Fraud Qui Tam Case 2Whistleblower Comments on Hawthorn Pharmaceuticals' $2.8 Million Settlement of His Medicaid Fraud Qui Tam Case 3
Nidek offers 3-Dx/F Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Eye Q PRO is the optimum choice for ophthalmologists and clinicians specializing in advanced pathology and research....
Nidek LM-990A accomplishes precise measurement, quick response and easy operation....
... is a diversified wide-angle fundus ... ICG (optional) with various magnifications, ... the market), 40 degrees for ... picture and 30 degrees for ...
Medicine Products: